ENDRA LIFE SCIENCES INC (NDRA) Stock Earnings & Estimates
USA - NASDAQ:NDRA - US29273B5003 - Common Stock
5.75 USD
-0.03 (-0.52%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 520K -63.12% | 350K -32.69% | 10K -97.14% | -100.00% | 229.5K | 714K | 306K | |||||
| EBITDA YoY % growth | -1.73M -15.33% | -4.57M -164.16% | -8.66M -89.50% | -10.394M -24.25% | N/A -5.95% | N/A 0.18% | N/A -14.76% | N/A 16.72% | N/A -0.71% | N/A | N/A | |
| EBIT YoY % growth | -1.79M -14.01% | -4.63M -158.66% | -8.73M -88.55% | -10.392M -24.17% | -13.284M -6.09% | -11.935M | -13.056M -14.43% | -12.444M 16.41% | -8.874M | -7.344M 33.24% | -9.486M -29.17% | |
| Operating Margin | -344.23% | -1,322.86% | -87,300.00% | N/A | N/A | -5,200.44% | -1,828.57% | N/A | N/A | N/A | -3,100.00% | |
| EPS YoY % growth | N/A | N/A | N/A | -46,945.50 | -25,704.00 68.38% | -9,996.00 62.16% | -7,854.00 18.57% | -3,302.25 60.31% | -48.41 -576.50% | -9.79 98.40% | -10.20 -4.17% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -2.72 71.45% | -2.72 64.58% | -2.64 -42.03% | -2.31 -34.81% | -2.63 3.37% | -2.63 3.37% |
| Revenue Q2Q % growth | 102K | 102K | 102K | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.04M -35.19% | -2.04M 52.52% | -2.244M -52.73% | -2.244M -72.47% | -2.55M -25.00% | -2.55M -25.00% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -1.71 98.78% | -2.32 | 0.61 | 26.15% |
| Q1 2025 Q2Q % growth | -1.86 99.59% | -3.99 | 2.13 | 53.36% |
| Q4 2024 Q2Q % growth | -7.69 -207.52% | -4.18 | -3.51 | -83.84% |
| Q3 2024 Q2Q % growth | -9.54 52.30% | -63.55 | 54.01 | 84.99% |
| Q2 2024 Q2Q % growth | -140.00 -551.16% | -124.95 | -15.05 | -12.04% |
| Q1 2024 Q2Q % growth | -455.00 -878.49% | -481.95 | 26.95 | 5.59% |
| Q4 2023 Q2Q % growth | -2.50 94.79% | -18.36 | 15.86 | 86.38% |
| Q3 2023 Q2Q % growth | -20.00 60.00% | -21.93 | 1.93 | 8.80% |
| Q2 2023 Q2Q % growth | -21.50 64.17% | -28.05 | 6.55 | 23.35% |
| Q1 2023 Q2Q % growth | -46.50 33.57% | -53.30 | 6.80 | 12.75% |
| Q4 2022 Q2Q % growth | -48.00 40.00% | -45.90 | -2.10 | -4.58% |
| Q3 2022 Q2Q % growth | -50.00 16.67% | -56.10 | 6.10 | 10.87% |
| Q2 2022 Q2Q % growth | -60.00 25.00% | -56.10 | -3.90 | -6.95% |
| Q1 2022 Q2Q % growth | -70.00 -16.67% | -76.50 | 6.50 | 8.50% |
| Q4 2021 Q2Q % growth | -80.00 20.00% | -81.60 | 1.60 | 1.96% |
| Q3 2021 Q2Q % growth | -60.00 60.00% | -76.50 | 16.50 | 21.57% |
| Q2 2021 Q2Q % growth | -80.00 60.00% | -71.40 | -8.60 | -12.04% |
| Q1 2021 Q2Q % growth | -60.00 79.31% | -76.50 | 16.50 | 21.57% |
| Q4 2020 Q2Q % growth | -100.00 91.67% | -147.90 | 47.90 | 32.39% |
| Q3 2020 Q2Q % growth | -150.00 67.39% | -176.80 | 26.80 | 15.16% |
| Q2 2020 Q2Q % growth | -200.00 35.48% | -275.40 | 75.40 | 27.38% |
| Q1 2020 Q2Q % growth | -290.00 21.62% | -341.70 | 51.70 | 15.13% |
| Q4 2019 Q2Q % growth | -1,200.00 | -293.25 | -906.75 | -309.21% |
| Q3 2019 Q2Q % growth | -460.00 | -308.55 | -151.45 | -49.08% |
| Q2 2019 Q2Q % growth | -310.00 | -316.20 | 6.20 | 1.96% |
| Q1 2019 Q2Q % growth | -370.00 | -306.00 | -64.00 | -20.92% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | 714K | -714K | -100.00% | |
| Q4 2021 Q2Q % growth | 229.5K | -229.5K | -100.00% | |
| Q3 2021 Q2Q % growth | 51K | -51K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 29.37% | 0% | 34.96% |
| Revenue | N/A | N/A | N/A | N/A |